International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial
08 oct. 2018 08h30 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
International Stem Cell Corporation Raised Funds Through a Private Placement at Premium to Market
02 oct. 2018 08h00 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
09 août 2018 08h00 HE
|
Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
International Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical Products
10 juil. 2018 07h00 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing...
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28 juin 2018 07h35 HE
|
Cocrystal Pharma, Inc.
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
25 juin 2018 08h00 HE
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...